Factors Influencing the Conversion of Ocular Myasthenia Gravis to Generalized Myasthenia Gravis: A Retrospective Cohort Study
Issued Date
2026-01-01
Resource Type
ISSN
2090004X
eISSN
20900058
Scopus ID
2-s2.0-105029821052
Journal Title
Journal of Ophthalmology
Volume
2026
Issue
1
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Ophthalmology Vol.2026 No.1 (2026)
Suggested Citation
Chuenkongkaew W., Chirapapaisan N., Chatchutimakorn P., Rattanathamsakul N., Joradoln M., Kongthanasomboon P., Eiamsamarng A. Factors Influencing the Conversion of Ocular Myasthenia Gravis to Generalized Myasthenia Gravis: A Retrospective Cohort Study. Journal of Ophthalmology Vol.2026 No.1 (2026). doi:10.1155/joph/6652248 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/115167
Title
Factors Influencing the Conversion of Ocular Myasthenia Gravis to Generalized Myasthenia Gravis: A Retrospective Cohort Study
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
Purpose: The conversion rate of ocular myasthenia gravis (OMG) to generalized myasthenia gravis (GMG) lacks definitive predictors. Methods: This retrospective cohort study analyzed data collected at Siriraj Hospital between January 2007 and December 2019 to identify factors influencing OMG generalization and the time to conversion. The records of 200 OMG patients were reviewed and both acetylcholine receptor antibody (AChR Ab)-positive and AChR Ab-negative patients were included. Results: Seventy-eight (39%) developed GMG, with a median conversion time of 16 months (IQR 7.88, 33.75) and a 2-year conversion rate of 25.5%. AChR Ab positivity (adjusted HR 2.88, 95% CI 1.79–4.63), thymic abnormalities (adjusted HR 2.30, 95% CI 1.41–3.74), smoking (adjusted HR 1.78, 95% CI (1.04, 3.03), and pyridostigmine dosages > 180 mg/day (adjusted HR 2.33, 95% CI 1.41–3.87) were significantly associated with shorter conversion time. Conclusion: Thymic abnormalities and positive AChR Ab warrant routine assessment in all OMG patients. Smoking cessation is crucial, as it may impact conversion risk and time. Unlike previous findings suggesting a protective role of pyridostigmine, our data indicate a strong association between high-dose pyridostigmine and conversion to GMG, likely reflecting underlying disease severity. This underscores the need for individualized risk assessment in OMG management.